Thyzol 5 Tablet

About Thyzol 5 Tablet

Thyzol 5 is a tablet made by Nuvista Pharma Ltd that contains methimazole 5 mg. It belongs to a group of anti-thyroid medicines that lower the body's production of thyroid hormone.

There are 5 brands of Methimazole listed in Bangladesh.

What is Thyzol 5 Tablet?

Thyzol 5 is an anti-thyroid tablet containing methimazole 5 mg, made by Nuvista Pharma Ltd. The thyroid gland normally makes hormones that control how fast the body works. Methimazole reduces the making of these hormones, but it does not remove hormone already stored in the thyroid gland or already present in the blood. It is used in people with an overactive thyroid, including Graves' disease and toxic multinodular goiter, when surgery or radioactive iodine is not suitable, and to ease symptoms before such treatment. The doctor decides the dose and how long it is taken.

Uses of Thyzol 5

Thyzol 5 is used for an overactive thyroid gland. This includes Graves' disease with hyperthyroidism and toxic multinodular goiter in people for whom surgery or radioactive iodine therapy is not an appropriate option. It is also used to reduce the symptoms of hyperthyroidism while preparing a patient for thyroid surgery or radioactive iodine therapy. Your doctor will explain whether this medicine suits your condition.

How to use Thyzol 5

Thyzol 5 is a tablet that is swallowed. Your doctor decides the dose, how often it is taken and for how long. Do not change the dose on your own. If you miss a tablet, ask your doctor or pharmacist what to do. Tell your doctor about all other medicines you take, because methimazole can interact with some of them, and the doctor may need to monitor you.

Side effects of Thyzol 5

Some people have skin rash, itching, nausea, vomiting, stomach discomfort, joint or muscle pain, tingling, loss of taste, hair loss, headache, drowsiness, dizziness, swelling, yellowing of the skin, or enlarged glands. Rare but serious effects include low blood cell counts, liver problems, fever and a lupus-like reaction. Tell your doctor promptly about any unusual symptom, especially sore throat, fever or yellowing of the skin.

Safety and precautions

Do not take Thyzol 5 if you are allergic to methimazole or any part of the tablet. Methimazole can harm an unborn baby, particularly in the first trimester, so tell your doctor if you are pregnant or planning pregnancy; other treatment may be more suitable. It passes into breast milk, and monitoring of the baby's thyroid function may be advised. Talk to your doctor before use if you have liver problems or low blood counts, and ask about any monitoring you need.

Frequently asked questions

What does the tablet form and the 5 mg strength mean?

Thyzol 5 comes as a tablet to be swallowed, not as a liquid or injection. The 5 mg refers to the amount of methimazole in each tablet. Your doctor decides how many tablets you take and when; never adjust this yourself.

What is Thyzol 5 used for and what kind of medicine is it?

It is an anti-thyroid medicine. It lowers the amount of thyroid hormone the body makes and is used in an overactive thyroid, including Graves' disease and toxic multinodular goiter, when surgery or radioactive iodine is not suitable, and to ease symptoms before such treatment.

How should Thyzol 5 be stored?

Keep the tablets in a cool, dry place below 30°C, away from light and out of reach of children. Do not use them after the expiry date. If you are unsure how to store them, ask your pharmacist.

Can I take Thyzol 5 with other medicines?

Methimazole can interact with some other medicines, including blood thinners and certain heart medicines. Tell your doctor or pharmacist about everything you take, including medicines bought without a prescription, so they can decide whether any change or monitoring is needed.

Indications

Methimazole is indicated:
  • In patients with Graves' disease with hyperthyroidism or toxic multinodular goiter for whom surgery or radioactive iodine therapy is not an appropriate treatment option.
  • To ameliorate symptoms of hyperthyroidism in preparation for thyroidectomy or radioactive iodine therapy.

Pharmacology

Methimazole inhibits the synthesis of thyroid hormones and thus is effective in the treatment of hyperthyroidism. The drug does not inactivate existing thyroxine and triiodothyronine that are stored in the thyroid or circulating in the blood nor does it interfere with the effectiveness of thyroid hormones given by mouth or by injection. Methimazole is readily absorbed in the gastrointestinal tract, metabolized in the liver, and excreted in the urine.

Dosage & Administration

Methimazole is administered orally. The total daily dosage is usually given in 3 divided doses at approximately 8 hour intervals.

Adults: The initial daily dosage is 15 mg for mild hyperthyroidism, 30 to 40 mg for moderately severe hyperthyroidism, and 60 mg for severe hyperthyroidism, divided into 3 doses at 8 hour intervals. The maintenance dosage is 5 to 15 mg daily.

Pediatric: Initially, the daily dosage is 0.4 mg/kg of body weight divided into 3 doses and given at 8 hour intervals. The maintenance dosage is approximately 1/2 of the initial dose.

Use in children & adolescents: Because of post-marketing reports of severe liver injury in pediatric patient treated with propylthiouracil, Methimazole is the preferred choice when an antithyroid drug is required for a pediatric patient.

Interaction

With medicine: Anticoagulants (oral)- Due to potential inhibition of vitamin K activity by methimazole, the activity of oral anticoagulants (e.g., warfarin) may be increased; additional monitoring of PT/INR should be considered, especially before surgical procedures. β-adrenergic blocking agents- Hyperthyroidism may cause an increased clearance of beta-blockers with a high extraction ratio. A dose reduction of beta-adrenergic blockers may be needed when a hyperthyroid patient becomes euthyroid. Digitalis glycosides- Serum digitalis levels may be increased when hyperthyroid patients on a stable digitalis glycoside regimen become euthyroid; a reduced dosage of digitalis glycosides may be needed. Theophylline- Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid; a reduced dose of theophylline may be needed.

With food: Always take at the same moment in regard to meals, food may affect absorption unpredictably.

Contraindications

Methimazole is contraindicated in the presence of hypersensitivity to the drug or any of the other product components.

Side Effects

Common: Skin rash, urticaria, nausea, vomiting, epigastric distress, arthralgia, paresthesia, loss of taste, abnormal loss of hair, myalgia, headache, pruritus, drowsiness, neuritis, edema, vertigo, skin pigmentation, jaundice, sialadenopathy, and lymphadenopathy.

Rare: Agranulocytosis, granulocytopenia, thrombocytopenia and aplastic anemia, drug fever, a lupus-like syndrome, insulin autoimmune syndrome (which can result in hypoglycemic coma), hepatitis (jaundice may persist for several weeks after discontinuation of the drug), periarteritis, and hypoprothrombinemia. Nephritis occurs very rarely.

Pregnancy & Lactation

Pregnancy Category D. Due to the rare occurrence of congenital malformations associated with methimazole use, it may be appropriate to use other agents in pregnant women requiring treatment for hyperthyroidism particularly in the first trimester of pregnancy. Methimazole is excreted into breast milk. However, several studies found no effect on clinical status in nursing infants of mothers taking methimazole, particularly if thyroid function is monitored at frequent (weekly or biweekly) intervals.

Precautions & Warnings

Congenital Malformations: Methimazole readily crosses the placental membranes and can cause fetal harm, particularly when administered in the first trimester of pregnancy. If Methimazole is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be warned of the potential hazard to the fetus. Since some congenital defects have been reported in offspring of patients treated with Methimazole, it may be appropriate to use other agents in pregnant women requiring treatment for hyperthyroidism, particularly in the first trimester of pregnancy. If Methimazole is used, the lowest possible dose to control the disease should be given.

Agranulocytosis: Agranulocytosis is potentially a life-threatening adverse reaction of Methimazole therapy. Patients should be instructed to immediately report to their physicians if any symptoms suggestive of agranulocytosis, such as fever or sore throat occur. Leukopenia, thrombocytopenia, and aplastic anemia (pancytopenia) may also occur. The drug should be discontinued in the presence of agranulocytosis, aplastic anemia (pancytopenia), ANCA-positive vasculitis, hepatitis, or exfoliative dermatitis and the patient’s bone marrow indices should be monitored.

Liver Toxicity: Although there have been reports of hepatotoxicity associated with Methimazole, the risk of hepatotoxicity appears to be less with methimazole than with propylthiouracil, especially in the pediatric population. Drug treatment should be discontinued promptly in the event of clinically significant evidence of liver abnormality including hepatic transaminase values exceeding 3 times the upper limit of normal.

Hypothyroidism: Methimazole can cause hypothyroidism necessitating routine monitoring of TSH and free T4 levels with adjustments in dosing to maintain a euthyroid state. Because the drug readily crosses placental membranes, Methimazole can cause fetal goiter and cretinism when administered to a pregnant woman. For this reason, it is important that a sufficient, but not excessive, dose be given during pregnancy. Because Methimazole may cause hypoprothrombinemia and bleeding, prothrombin time should be monitored during therapy with the drug, especially before surgical procedures. Thyroid function tests should be monitored periodically during therapy. Once clinical evidence of hyperthyroidism has resolved, the finding of a rising serum TSH indicates that a lower maintenance dose of Methimazole should be employed.

Overdose Effects

Symptoms may include nausea, vomiting, epigastric distress, headache, fever, joint pain, pruritus, and edema. Aplastic anemia or agranulocytosis may be manifested in hours to days. Less frequent events are hepatitis, nephrotic syndrome, exfoliative dermatitis, neuropathies, and CNS stimulation or depression. In the event of an overdose, appropriate supportive treatment should be initiated as dictated by the patient’s medical status.

Storage Conditions

Store in a cool (below 30°C) and dry place, away from light and children.

Alternative brands of Methimazole

Other brands with the same generic name, cheapest first.

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.